Recent studies have confirmed that, in addition to MSI, EBV, and PD-L1, TMB can also be used as a biomarker to predict the prognosis of patients with advanced gastric cancer who receive immune checkpoint inhibitors [23]. This evidence concerns the gene CD274 and gastric cancer.